Devi Jai, Boora Ankit, Rani Manju, Arora Tanisha
Department of Chemistry, Guru Jambheshwar University of Science and Technology, Hisar-125001, Haryana, India.
Anticancer Agents Med Chem. 2023;23(2):164-191. doi: 10.2174/1871520622666220520095549.
Cancer cases have escalated by approximately 12% since 1900 and the incidence rate has increased faster for females than males. The discovery of cisplatin in 1965 paved the way for metal-based compounds as cancer therapeutics. Unfortunately, cisplatin and other platinum-based medicines cause severe side effects. Therefore, non-platinum metal complexes have been developed as alternate cancer drugs. Among non-platinum metal complexes, organotins are the most effective candidates in oncology due to their wide range of anticancer activities with relatively minimal toxicities towards healthy cells, better excretion from the body, and fewer side effects than platinum drugs.
Using DOI searching, advances made by organotin(IV) complexes coordinated with Sn-O, Sn-N and Sn-S as chemotherapeutic agents since 2018 are summarized in this article. Their chemical structure and in vitro antiproliferative activity in terms of IC/EC/LD are cumulated.
As reflected in this perspective, organotin(IV) complexes are found to induce high cell death via apoptosis, and also several complexes demonstrated anticancer activity even higher than standard drugs.
Undoubtedly, the organotin(IV) complexes could bring hope to morbidity and mortality of human beings caused by fast-spreading cancer worldwide and can play an important role in drug discovery.
自1900年以来,癌症病例增加了约12%,女性的发病率增长速度快于男性。1965年顺铂的发现为金属基化合物作为癌症治疗药物铺平了道路。不幸的是,顺铂和其他铂类药物会引起严重的副作用。因此,已开发出非铂金属配合物作为替代癌症药物。在非铂金属配合物中,有机锡由于其广泛的抗癌活性、对健康细胞的毒性相对较小、从体内更好的排泄以及比铂类药物更少的副作用,是肿瘤学中最有效的候选药物。
通过数字对象标识符(DOI)搜索,本文总结了自2018年以来与Sn-O、Sn-N和Sn-S配位的有机锡(IV)配合物作为化疗药物取得的进展。累积了它们的化学结构以及在半数抑制浓度(IC)/半数效应浓度(EC)/半数致死剂量(LD)方面的体外抗增殖活性。
从这个角度来看,发现有机锡(IV)配合物通过凋亡诱导高细胞死亡,并且一些配合物表现出甚至高于标准药物的抗癌活性。
毫无疑问,有机锡(IV)配合物可以为全球快速传播的癌症给人类带来的发病率和死亡率带来希望,并且在药物发现中可以发挥重要作用。